Page 6 - Cadila Healthcare

Cadila's Moraiya plant successfully completes USFDA inspection

Shares of Cadila Healthcare on Thursday closed 3.41% higher at Rs 512.60 per scrip on BSE

US sales give Cadila Healthcare an edge over peers

Faster product-approval rate leads to higher earnings growth visibility

Cadila Healthcare up 7% on USFDA approval for antipsychotic drug

The stock was up 7% to Rs 496 on BSE in otherwise range-bound market.

Cadila Healthcare Q1 PAT down 30% as GST hurts domestic business

Cadila Healthcare (or Zydus Cadila) posted a 30 per cent year on year (YoY) drop in standalone net profit for the quarter ended June 30, 2017 to Rs 91.4 crore, while its sales grew by 14 per cent to Rs 1000.4 crore.For the first quarter of the current financial year, Zydus Standalone sales grew by 14 per cent from Rs 875 crore in the corresponding quarter last fiscal. At the same time, its net profit fell 30 per cent from Rs 130.4 crore in Q1FY17. On a consolidated basis, the company posted a 4.2 per cent drop in sales to Rs 2167.2 crore in Q1FY18 from Rs 2262.4 crore in Q1FY17. Its net profit fell 65 per cent to Rs 138.4 crore in the quarter under review from Rs 398.4 crore in Q1FY17. Sarabjit Kour Nangra, vice president, research, pharma, Angel Broking felt that the poor numbers are mainly driven by the Indian formulation sales dip. Cadila's key market US, however, saw a 14 per cent growth. "Indian formulation sales (Rs 637.4 crore), a YoY dip of 18.9 per cent. Its key market USA ...

Cadila poised to join billion-dollar sales club in US by FY20

Cipla, Glenmark Pharma to catch up by FY21-22

Troubles behind it, Cadila surges ahead

Cadila hopes to double its revenue from the US in three years

Cadila Healthcare aims to double US business to $1 billion in 3 years

Pharma major to launch 100 new products; Moraiya facility slated to come out of US FDA woes

USFDA audit finds no flaws in Cadila Healthcare Moraiya unit

Plant has received several product approvals after audit. eyes 40 in all in FY18

Cadila Healthcare hits new high on USFDA approval for new drug

The stock rallied 10% to Rs 539, also its new high on BSE in intra-day trade

Cadila Healthcare at new high on getting EIR from USFDA for Baddi facility

In past eight trading days, the stock gain 17% as compared to 1.8% rise in the S&P BSE Sensex

Cadila's US business hopes soar on Moraiya plant approval

The US market contributes around 40% to the company's revenues

Cadila Healthcare hits record high on USFDA approval for Levofloxacin

The group now has more than 115 approvals and has so far filed over 300 ANDAs

Cadila Healthcare posts Q4 net profit at Rs 385 crore

Consolidated total revenue of company stood at Rs 2,598 crore for quarter under consideration.

Cadila Healthcare says Changodar plant has got no USFDA observation

The plant was inspected by the US FDA between April 3 and April 7

Cadila Healthcare's Changodar plant gets no USFDA observation; shares rise

In February, the company's Moraiya unit too did not receive any observations from USFDA

US regulator observations at Baddi unit may not effect Cadila

Ahmedabad-headquartered Cadila Healthcare has today informed the Bombay Stock Exchange (BSE) that its Baddi plant has received three observations from the US Food and Drug Administration (USFDA) related to a pre-approval inspection (PAI) for a specific product filed. While the company's shares on the BSE tanked 1.76 per cent in day's trade, analysts say this would have no immediate impact on revenues. Cadila Healthcare said in its statement that the USFDA had inspected its formulations manufacturing facility at Baddi from February 20 to March 1 and at the end of the inspection, there were three observations given under form 483. "All these three observations are related to Pre-Approval Inspection (PAI) for a specific product filed. This product is yet to be manufactured or marketed in the US. The company is already in the process of responding to the PAI observations. Apart from above product related observations, there are no observations related to cGMP practices," it said.As per ...

Cadila Healthcare inches closer to net profit upgrades

The company is on course to sort out various issues raised by the FDA

Cadila shares extend gains; surge nearly 5%

USFDA has inspected its Moraiya plant and found the unit complying with manufacturing norms

Cadila inches closer to net profit upgrades

Higher competitive intensity in US base business impacted Q3 and will keep the stock under pressure

Cadila shares soar 20%; mcap surges by Rs 7,309 cr

Led by sharp surge in the stock, its market valuation rose to Rs 43,964.63 crore